

20 September 2023

Biologic & Biosimilar Treatments for Rheumatology & Psoriatic Arthritis

We are analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could answer the following two questions:

1. Could you please provide the numbers of patients treated by the Rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]	IV 46 & SC 217
• Adalimumab [Humira]	398
• Adalimumab Biosimilars	Amgevita 178 & Imraldi 594
• Apremilast [Otezla]	29
• Baricitinib [Olumiant]	44
• Bimekizumab [Bimzelx]	0
• Certolizumab [Cimzia]	127
• Etanercept [Enbrel]	127
• Etanercept Biosimilars	Benepali 342
• Filgotinib [Jyseleca]	<5
• Golimumab [Simponi]	100
• Guselkumab [Tremfya]	8
• Infliximab [Remicade]	53
• Infliximab Biosimilars	IV Remsima 43 & SC Remsima <5
• Ixekizumab [Taltz]	82
• Risankizumab [Skyrizi]	<5
• Rituximab [MabThera]	86
• Rituximab Biosimilars	Truxima 190
• Sarilumab [Kevzara]	<5
• Secukinumab [Cosentyx]	240
• Tocilizumab [Ro Actemra]	IV 50 & SC 148
• Tofacitinib [Xeljanz]	26
• Upadacitinib [Rinvoq]	84
• Ustekinumab [Stelara]	14

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information (FOI) Act as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

20 September 2023

2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:

• Abatacept [Orencia]	IV <5 & SC 6
• Adalimumab [Humira]	131
• Adalimumab Biosimilars	Amgevita 46 & Imraldi 189
• Apremilast [Otezla]	25
• Bimekizumab [Bimzelx]	0
• Certolizumab [Cimzia]	46
• Etanercept [Enbrel]	24
• Etanercept Biosimilars	Benepali 104
• Golimumab [Simponi]	53
• Guselkumab [Tremfya]	8
• Infliximab [Remicade]	14
• Infliximab Biosimilars	IV Remsima 13
• Ixekizumab [Taltz]	51
• Risankizumab [Skyrizi]	0
• Secukinumab [Cosentyx]	158
• Tofacitinib [Xeljanz]	5
• Upadacitinib [Rinvoq]	14
• Ustekinumab [Stelara]	7

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the FOI Act.